Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Sponsor: University Health Network, Toronto
Summary
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Official title: Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer: a Randomized Phase II Trial
Key Details
Gender
MALE
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2025-07-08
Completion Date
2030-06
Last Updated
2025-09-05
Healthy Volunteers
No
Interventions
Stereotactic Body Radiation Therapy (SBRT)
SBRT will be delivered as per institutional standard.
Systemic therapy
Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.
Locations (1)
Princess Margaret Cancer Center
Toronto, Ontario, Canada